Kobner PhenomenonRENBOEKNCT06021405
Koebner's Phenomenon in Psoriasis and Lichen Planus
A study testing Tape stripping in people with Kobner Phenomenon and Psoriasis, run by Marie-Charlotte Brüggen.
Trial summary
Psoriasis and lichen planus often occur at mechanically irritated skin sites (e.g. tight clothing). The investigators would like to investigate this phenomenon in more detail in this study. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Kobner Phenomenon, Psoriasis, Lichen Planus
- What is being tested?
- Tape stripping
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2025to 20 Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Dermatologist diagnosed psoriasis (group psoriasis), lichen planus (group lichen planus) or no skin disease (group healthy controls)
- Subject is capable of giving informed consent
- Signed informed consent
Who cannot join
- Use of systemic immunosuppressive/immunmodulating agents in the last three months
- Use of topical anti-inflammatory treatment in the last 7 days in the area of sampling.
- Phototherapy in the last 4 weeks
- Active or recurrent serious bacterial, fungal or viral infection at the time of enrollment by patient history, including patients with Human Immunodeficiency Virus (HIV) infection, Hepatitis B and Hepatitis C infection, active or untreated latent tuberculosis.
- Female patients of childbearing potential who are pregnant or breast feeding or planning a pregnancy during the duration of the trial and/or not practicing acceptable birth control for the duration of the trial
- Known or suspected non-compliance, drug or alcohol abuse,
Show all 9Show fewer
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
- Previous enrolment into the current study,
- Enrolment of the investigator, his/her family members, employees and other dependent persons.
About this study
Official title: A Prospective Study to Investigate the Pathophysiology of the Koebner's Phenomenon in Psoriasis and Lichen Planus
Psoriasis and lichen planus often occur at mechanically irritated skin sites (e.g. tight clothing). The investigators would like to investigate this phenomenon in more detail in this study. For this purpose, the skin is specifically irritated at a small and cosmetically favorable site by tearing off scotch tape or rubbing with a wooden spatula. In order to be able to examine the inflammatory processes caused by the irritation more closely, a small skin sample and a skin swab are taken from the irritated area. This skin sample and the swab are repeated after three and fourteen days.
- Conditions
- Kobner Phenomenon, Psoriasis, Lichen Planus
- Being tested
- Tape stripping
- Medical subject headings
- Psoriasis, Lichen Planus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tape strippingProcedure or surgery
a small area of skin will be tape-stripped with adhesive tape for up to 40 times and/or rubbed with a wooden spatula until the skin shows a slight erythema
| Study group | Role | What they receive |
|---|---|---|
| Tape stripping | Experimental | Not described Receives: Procedure: Tape stripping |
What is being measured
The primary outcome is the main question the study is designed to answer.
Differences in the transcriptomic profile comparing psoriasis patients with and without induced koebner phenomenon
Transcriptomic profile at all timepoints (reads per 55µm diameter dot)
Measured: Day 0, Day 3 (optional), Day 14 (optional)
Secondary outcomes (3)
Differences in the proteomic profile comparing psoriasis patients with and without induced koebner phenomenon
Olink multiplex proteomics analysis at all timepoints
Measured: Day 0, Day 3 (optional), Day 14 (optional)
Characterization of involved immune cells in the skin comparing psoriasis patients with and without induced koebner phenomenon
Imaging mass cytometry (skin biopsies) at all timepoints
Measured: Day 0, Day 3 (optional), Day 14 (optional)
Characterization of skin mikrobiome
Skin swabs at all timepoints, analyzed by isolation and sequencing of the microbial DNA
Measured: Day 0, Day 3, Day 14
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2023
- Study start1 Sep 2025
- Primary completion20 Sep 2025
- Study completion20 Sep 2025
Why it stopped: due to personnel and financial restrictions, the study could not be conducted
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Kobner PhenomenonStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Marie-Charlotte Brüggen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Marie-Charlotte Brüggen, University of Zurich
- Investigators
- Marie-Charlotte Brüggen, MD PhD, Principal investigator, University of Zurich
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06021405
- Sponsor's protocol ID
- 2023-00427
- Other IDs
- 2023
- Acronym
- RENBOEK
- Status last verified
- Mar 2025
- First submitted
- 11 Aug 2023
- Last updated
- 17 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Study to Investigate the Pathophysiology of the Koebner's Phenomenon in Psoriasis and Lichen Planus
- ClinicalTrials.gov ID
- NCT06021405
- Acronym / sponsor ID
- RENBOEK / 2023-00427
- Conditions
- Kobner Phenomenon, Psoriasis, Lichen Planus
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: due to personnel and financial restrictions, the study could not be conducted
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Marie-Charlotte BrüggenUniversity, hospital or other
- Study start
- 1 Sep 2025 (actual)
- Primary completion
- 20 Sep 2025 (actual)
- Study completion
- 20 Sep 2025 (actual)
- First posted
- 1 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Psoriasis and lichen planus often occur at mechanically irritated skin sites (e.g. tight clothing). The investigators would like to investigate this phenomenon in more detail in this study. For this purpose, the skin is specifically irritated at a small and cosmetically favorable site by tearing off scotch tape or rubbing with a wooden spatula. In order to be able to examine the inflammatory processes caused by the irritation more closely, a small skin sample and a skin swab are taken from the irritated area. This skin sample and the swab are repeated after three and fourteen days.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Tape stripping | Experimental | Procedure: Tape stripping |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Dermatologist diagnosed psoriasis (group psoriasis), lichen planus (group lichen planus) or no skin disease (group healthy controls)
- Subject is capable of giving informed consent
- Signed informed consent
Key exclusion criteria (9 listed)
- Use of systemic immunosuppressive/immunmodulating agents in the last three months
- Use of topical anti-inflammatory treatment in the last 7 days in the area of sampling.
- Phototherapy in the last 4 weeks
- Active or recurrent serious bacterial, fungal or viral infection at the time of enrollment by patient history, including patients with Human Immunodeficiency Virus (HIV) infection, Hepatitis B and Hepatitis C infection, active or untreated latent tuberculosis.
- Female patients of childbearing potential who are pregnant or breast feeding or planning a pregnancy during the duration of the trial and/or not practicing acceptable birth control for the duration of the trial
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tape strippinga small area of skin will be tape-stripped with adhesive tape for up to 40 times and/or rubbed with a wooden spatula until the skin shows a slight erythema | Procedure or surgery | Tape stripping |
Primary outcome
Differences in the transcriptomic profile comparing psoriasis patients with and without induced koebner phenomenon
Time frame: Day 0, Day 3 (optional), Day 14 (optional)
Transcriptomic profile at all timepoints (reads per 55µm diameter dot)
3 secondary outcomes
Differences in the proteomic profile comparing psoriasis patients with and without induced koebner phenomenon
Time frame: Day 0, Day 3 (optional), Day 14 (optional)
Characterization of involved immune cells in the skin comparing psoriasis patients with and without induced koebner phenomenon
Time frame: Day 0, Day 3 (optional), Day 14 (optional)
Characterization of skin mikrobiome
Time frame: Day 0, Day 3, Day 14
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Mar 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marie-Charlotte Brüggen, MD PhD principal investigator
University of Zurich
Questions about this trial
What is this clinical trial studying?
A study testing Tape stripping in people with Kobner Phenomenon and Psoriasis, run by Marie-Charlotte Brüggen.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 17 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Differences in the transcriptomic profile comparing psoriasis patients with and without induced koebner phenomenon (time frame: Day 0, Day 3 (optional), Day 14 (optional)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2026.